Summary
Bristol-Myers Squibb Company (BMY) filed an 8-K on January 24, 2013, to announce its financial results for the fourth quarter and full year of 2012. The report primarily references a press release issued on the same date, which contains the detailed financial outcomes and operational highlights for the period. Investors should refer to this press release and accompanying supplemental information for a comprehensive understanding of the company's performance.
Key Highlights
- 1BMY filed an 8-K on January 24, 2013, reporting on its Q4 and full-year 2012 financial results.
- 2The primary purpose of the filing is to furnish a press release announcing these financial results.
- 3The press release, dated January 24, 2013, is included as Exhibit 99.1.
- 4Additional supplemental financial information is available on the company's website and is furnished as Exhibit 99.2.
- 5Investors are directed to these exhibits for detailed financial performance and operational data.
- 6The filing does not contain new operational disclosures beyond what is presented in the press release and supplemental information.
Frequently Asked Questions
The main purpose of this 8-K filing is to officially report Bristol-Myers Squibb's financial results for the fourth quarter and the full year of 2012. This is typically done by referencing an accompanying press release.
The detailed financial results are primarily contained in the press release issued by Bristol-Myers Squibb on January 24, 2013, which is furnished as Exhibit 99.1 to this 8-K filing. Supplemental information is also available as Exhibit 99.2.
This 8-K filing itself does not provide new guidance. The financial results and any forward-looking statements or outlook would be detailed within the referenced press release (Exhibit 99.1) and supplemental information (Exhibit 99.2).
The financial results reported in this filing are for the fourth quarter and the twelve months (full year) of 2012.